Fiji Kava on Friday lodged its prospectus for listing on the Australian Stock Exchange, which is scheduled to happen later this month.
The high-end kava producer says it intends to raise $AU5.2 million from investors at 20 cents per share.
Some of the money will go towards research for treating anxiety, insomnia and pain with kava, said its chairperson, Andrew Kelly.
"That will be clinical trials with humans and that will be done with varying extracts of kava, trying to refine the effect and the quality of what we are able to deliver to Western markets."
